comparemela.com

Latest Breaking News On - Rhythm therapeutics - Page 1 : comparemela.com

Follow the Money: Single-Cell Analysis, Spatial Biology, Drug-Resistant Infection Treatments, 3D Genomics

Follow the Money: Single-Cell Analysis, Spatial Biology, Drug-Resistant Infection Treatments, 3D Genomics
bio-itworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bio-itworld.com Daily Mail and Mail on Sunday newspapers.

Rhythm Therapeutics rebrands as Inomagen Therapeutics

Inomagen Therapeutics is developing a revolutionary gene therapy to improve the treatment of atrial fibrillation, a condition afflicting 37 million people worldwide; Submits Phase 1 Segment interim results to NIH; Phase 1 completion planned by the end of this year.

Rhythm Therapeutics, Inc Awarded $3 67 million NIH SBIR Fast Track Grant to Develop Gene Therapy for Atrial Fibrillation

Rhythm Therapeutics, Inc. Awarded $3.67 million NIH SBIR Fast Track Grant to Develop Gene Therapy for Atrial Fibrillation Share Article Chicago-based Rhythm Therapeutics is led by founder Dr. Rishi Arora, Professor of Medicine, Clinical Cardiac Electrophysiology at Northwestern University - The Feinberg School of Medicine; Grant is from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, and from the Small Business Innovation Research program that can total up to $3.67 million; Atrial fibrillation is the most common heart rhythm disorder, affecting six million people in the U.S. and 33 million worldwide. Rishi Arora, MD, FHRS, FAHA

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.